Bedside Vigilance: Practical Escalation Protocols for CAR-T Cytokine Release Syndrome and ICANS

The Crucial Window of First-Line Bedside Vigilance

CAR-T toxicities can move from an apparently modest fever to respiratory compromise, vasoplegic shock, or rapidly evolving encephalopathy within hours. Cytokine release syndrome, or CRS, reflects systemic immune activation after cellular therapy and commonly presents with fever, hypotension, and hypoxia. Immune effector cell-associated neurotoxicity syndrome, or ICANS, may emerge later, often around days five to nine, with word-finding difficulty, impaired attention, tremor, handwriting changes, somnolence, or seizures. In clinical practice, the most consequential observations are often small changes that appear before a patient meets criteria for severe toxicity.

Meticulous surveillance is therefore an intervention, not merely documentation. A nurse who recognizes a rising heart rate, narrowing pulse pressure, increasing oxygen requirement, or subtle language hesitation can activate the treatment pathway while the patient remains responsive to fluids, oxygen, and protocol-directed medication. The published monitoring evidence underscores why immune effector cell expansion requires disciplined fluid assessment and frequent reassessment. ASTCT grading supplies a common language, but bedside vigilance turns that language into minute-by-minute action, clear communication, and timely multidisciplinary escalation.

Deciphering Early CRS Hemodynamics and Temperature Kinetics

ASTCT defines CRS beginning with a temperature of at least 38°C that is not attributable to another cause, although fever may be absent after antipyretics or anti-cytokine treatment. The pattern matters. A low-grade fever that remains stable is clinically different from a rapidly rising temperature accompanied by rigors, tachycardia, increasing respiratory rate, or a new sense of weakness. The nurse should confirm the measurement, review recent medications, assess for infection, and avoid assuming that every post-infusion fever is either benign or definitively CRS.

Early circulatory compromise may precede an obvious blood pressure fall. Compensatory tachycardia, delayed capillary refill, cool extremities, reduced urine output, dizziness, and a narrowing pulse pressure can signal declining effective circulating volume or evolving vasodilation. Compare current findings with the patient”s baseline rather than relying only on a single threshold. Fluid balance should include oral intake, intravenous therapy, urine output, daily weight when appropriate, and signs of pulmonary congestion. This distinction is essential because aggressive fluids may support a patient with early, fluid-responsive hypotension but can worsen pulmonary edema when capillary leak or myocardial dysfunction is present.

When CRS is suspected, follow the institutional cellular therapy pathway without delaying essential evaluation. Typical immediate actions include obtaining blood cultures and other ordered infectious studies, checking laboratory markers, reassessing airway and breathing, establishing reliable intravenous access, and notifying the responsible clinician or rapid response team according to local criteria. A stat fluid challenge should be administered only within the patient”s prescribed protocol and with repeated lung, oxygenation, and hemodynamic assessment. Escalation should occur before hypotension becomes refractory, especially when the patient has cardiac, renal, pulmonary, or frailty-related risk factors.

• Trend temperature, heart rate, blood pressure, pulse pressure, respiratory rate, oxygen saturation, mental status, and urine output rather than recording isolated values.
• Document the timing of fever, fluids, antipyretics, oxygen changes, cultures, tocilizumab, corticosteroids, and vasopressor initiation.
• Escalate promptly for persistent hypotension, increasing oxygen need, altered perfusion, new arrhythmia, respiratory distress, or a clinical trajectory that is worsening despite initial measures.

Actionable ASTCT Cytokine Release Syndrome Triage Table

ASTCT grading separates CRS severity according to fever, hypotension, and hypoxia. Fever establishes the syndrome, while the highest level of hypotension or hypoxia determines the grade. The grading system does not replace assessment of renal, cardiac, hepatic, infectious, neurologic, or coagulation complications. It is also important to recognize that antipyretics, tocilizumab, or corticosteroids may suppress fever, so subsequent deterioration must still be interpreted in the context of the preceding inflammatory course.

The following bedside framework summarizes the commonly used ASTCT approach. Local policy, product-specific requirements, and prescriber orders remain controlling, particularly for fluid volumes, oxygen devices, vasopressor selection, and medication dosing.

At Grade 1, the critical nursing task is preparation and surveillance. At Grade 2, reassess after every intervention and avoid labeling the patient “fluid responsive” without objective improvement in perfusion and blood pressure. At Grades 3 and 4, vasopressor-dependent shock or escalating respiratory support requires critical care involvement. Tocilizumab is generally the principal first-line pharmacologic treatment for significant CRS, but it should be administered under the approved protocol and without delaying airway, oxygen, vascular access, cultures, or vasopressor support when clinically necessary. The ASTCT practice guidelines should be used alongside the treating center”s current order sets and product-specific procedures.

Catching Micro-Changes in ICE Scores and Subtle Dysgraphia

ICANS often begins with changes that are easy to dismiss as fatigue, medication effect, anxiety, or poor sleep. Early findings include difficulty finding words, reduced attention, impaired calculation, tremor, slowed responses, handwriting impairment, and expressive aphasia. A patient may remain pleasant and oriented while struggling to name an object or write a familiar sentence. Because the ICE score is not perfectly sensitive or specific, a normal or near-normal score does not override a concerning neurological change. Infection, metabolic disturbance, stroke, hemorrhage, sedatives, steroid effects, and other central nervous system conditions remain important differential diagnoses.

A consistent handwriting sample can make subtle deterioration visible. Ask the patient to write a familiar sentence or a standardized phrase using the same type of paper and pen when possible. Compare spacing, letter formation, line control, tremor, pressure, omissions, and the time required. Motor hesitation, progressively smaller writing, irregular spacing, or an inability to complete a previously familiar task should be reported with the exact time and observed behavior. Research and clinical reviews examining CAR-T neuro-monitoring cohorts provide further detail on the importance of these early motor-language changes, including subtle dysgraphia assessment.

1. Orientation. Ask the patient to state the current year, month, city, and hospital. Award one point for each correct response, for a maximum of four.
2. Naming. Show three familiar objects and ask the patient to name each one. Award one point per correct answer, for a maximum of three.
3. Command following. Ask the patient to follow a simple command, such as holding up two fingers. Award one point for correct performance.
4. Writing. Ask the patient to write a standard sentence. Award one point when the sentence is grammatically meaningful and written without major impairment.
5. Attention. Ask the patient to count backward from 100 by tens. Award one point when completed correctly.

The total ICE score is 10 points. Record the component-level performance, not only the total, because a single new deficit may be clinically meaningful even when the aggregate score remains high. Perform assessments at the frequency required by the patient”s risk profile and institutional policy, and repeat after any change in speech, behavior, motor control, level of consciousness, or seizure activity. New focal findings, rapidly declining responsiveness, severe headache, repeated vomiting, or seizure activity require immediate escalation and evaluation for causes beyond uncomplicated ICANS.

Rapid Pharmacologic Escalation Pathways for ICANS and CRS

Tocilizumab and corticosteroids have different therapeutic roles. Tocilizumab blocks the interleukin-6 receptor and is principally used for clinically significant CRS. It can improve fever, hypotension, and hypoxia related to CRS, but it should not be considered adequate treatment for isolated ICANS. The blood-brain barrier creates a practical paradox: systemic IL-6 receptor blockade may control peripheral inflammation without reliably treating the inflammatory processes within the central nervous system. For a patient with progressive neurotoxicity, dexamethasone or another protocol-directed corticosteroid becomes central to management, with dose and route determined by ICANS severity and institutional guidance.

Medication timing must be coordinated with ongoing diagnostic and supportive care. A patient with possible ICANS needs airway and aspiration assessment, medication review, glucose and metabolic evaluation, and consideration of neuroimaging, electroencephalography, or neurology consultation when indicated. Corticosteroids may affect infection risk, glycemic control, mood, sleep, and neurological interpretation, so every dose should be documented with the indication, time, response, and subsequent examination. Evidence regarding precise steroid timing and dosing continues to evolve, making adherence to the current cellular therapy protocol particularly important.

• Institute seizure precautions and ensure rescue medication and monitoring equipment are immediately available according to policy.
• Use aspiration precautions for dysphagia, reduced alertness, weak cough, vomiting, or declining airway protection; keep oral intake restricted when clinically indicated.
• Repeat the ICE assessment and focused neurological examination after treatment and at the ordered interval, documenting changes in individual components.
• Trigger urgent critical care review for progressive somnolence, inability to protect the airway, recurrent seizures, severe agitation, escalating oxygen needs, unstable blood pressure, or suspected cerebral edema.
• Communicate in a structured format that includes CAR-T product and infusion date, CRS and ICANS grades, treatment times, vital-sign trends, ICE components, urine output, oxygen support, and response to interventions.

Severe ICANS and CRS may coexist, but their treatments are not interchangeable. Tocilizumab may be appropriate for concurrent CRS, while corticosteroids are generally required for clinically significant ICANS. Nurses should not wait for a dramatic decline before contacting the prescriber, pharmacist, neurologist, or intensive care team. Early multidisciplinary review allows the team to distinguish inflammatory toxicity from sepsis, bleeding, stroke, medication effect, or other emergencies while preserving time for reversible intervention.

Mastering the Bedside Shift to Protect Patient Outcomes

The strongest bedside defense combines precise vital-sign trending with structured neurological observation. Temperature kinetics, compensatory tachycardia, pulse pressure, perfusion, oxygen requirement, fluid response, handwriting, speech, attention, and ICE components create a clinical trajectory that is more informative than any isolated value. Consistent documentation also improves handoffs between nursing shifts and gives the treating team a reliable basis for judging whether a patient is improving, plateauing, or deteriorating.

Every member of the care team should have clear authority to activate the escalation pathway when the pattern is concerning. Early intervention does not mean indiscriminate medication or automatic intensive care transfer. It means recognizing risk while the patient still has physiologic reserve, communicating specific findings, and applying the correct intervention for CRS, ICANS, or an alternative diagnosis. Proactive bedside care protects patient safety, supports continuation of effective cellular therapy, and reduces the likelihood that a preventable Grade 1 warning sign will become multi-organ toxicity.